Among treatment-naive adults with advanced HIV disease, integrase inhibitors are a preferred first-line therapy over protease inhibitors.
The World Health Organization (WHO) has released updated recommendations on HIV clinical management providing new and revised ...
According to a new study, single-tablet regimens may provide better virologic response and control than multiple-tablet regimens for people living with HIV, likely due to a lower pill burden and, ...
Viral suppression is one of the major goals of the Centers for Disease Control and Prevention (CDC) Ending the HIV Epidemic in the US (EHE) initiative. 1 Viral suppression is defined in this context ...
In patients with HIV infection on rifampicin TB therapy, twice-daily bictegravir/emtricitabine/tenofovir alafenamide results ...
Please provide your email address to receive an email when new articles are posted on . Traditional combined antiretroviral therapy — or cART — and alternative cART were similarly effective in ...
Women who used a dolutegravir-based regimen had less mother-to-infant transmission of HIV compared with those on efavirenz-based regimens. Approximately 2.58 million children aged 0 to 19 years around ...
– Phase 3 Results from ARTISTRY-1 and 2 Trials will Form the Basis of Regulatory Submissions – FOSTER CITY, Calif., November 13, 2025--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today ...
Brazil's Health Regulatory Agency (Anvisa) approved on Monday the use of the drug Sunlenca (lenacapavir) for HIV-1 prevention ...
Johnson & Johnson announced today that scientists at Beth Israel Deaconess Medical Center (BIDMC), Crucell Holland B.V, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and several ...
The first PrEPVacc volunteer participant receives an injection at the launch of the launch of the PrePVacc Trial at the Masaka site of the MRC/UVRI and LSHTM Uganda Research Unit, on Tuesday 15 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback